Mitigating Risk of Validated Analytical Procedure Failures When Upgrading or Replacing LC Assets: Harnessing the Power of Quality by Design (QbD) Principles

Importance of the Topic

Keeping liquid chromatography (LC) instrumentation current is critical for high-performing analytical laboratories. Timely upgrades drive innovation, product quality, and commercial success. However, replacing or upgrading validated LC systems carries perceived risks of requiring full method revalidation, regulatory delays, and unpredictable performance issues. A proactive, structured approach is needed to manage these risks and maintain confidence in analytical results when assets change.

Objectives and Article Overview

This white paper by McGregor, Hong, and Pham presents an instrument-focused Quality by Design framework (iQbD) to mitigate the risk of validated analytical procedure failures during LC asset upgrades or replacements. The objectives are to define a systematic process for assessing instrument differences, to develop control and adjustment strategies, and to demonstrate suitability without triggering full method revalidation.

Methodology

The iQbD process is organized into four lifecycle stages:

• Stage 1 – Instrument Understanding: Knowledge gathering through process mapping, risk statements, Ishikawa diagrams, and specification review; experimental measurement of extra-column and dwell volumes.
• Stage 2 – Demonstration of Instrument Suitability: Execution of a performance qualification protocol using standardized Quality Control Reference Materials (QCRMs) and comparison of key metrics against a predefined Instrument Suitability Target (IST).
• Stage 3 – Ongoing Monitoring: Integration of the new instrument into routine calibration, maintenance, and performance monitoring programs using independent test solutions.
• Stage 4 – Retirement/Replacement: Safe decommissioning and disposal of retired assets in compliance with environmental and safety regulations.

Risk assessment employs a heat-map approach to classify instrument variables (tubing dimensions, flow ranges, mixing mechanisms, injection precision, etc.) as high, medium, or low risk. High and medium risks drive the development of control and adjustment strategies to align the new system with existing method requirements.

Instrumentation Used

■ Waters Alliance e2695 HPLC system (existing)
■ Waters Arc HPLC system (upgraded)
■ Quality Control Reference Materials (QCRMs) for gradient performance testing
■ Standard LC columns, solvents, and consumables for method transfer exercises

Main Findings and Discussion

An example risk assessment for transferring a gradient method from an Alliance e2695 to an Arc HPLC system identified differences in extra-column volume, dwell volume, and mixing mechanics. By applying the iQbD framework, tubing and mixer adjustments were specified in a control strategy. Stage 2 testing with QCRMs confirmed that both systems met the IST for retention time precision, resolution, and sensitivity, avoiding full method revalidation.

Benefits and Practical Applications

■ Avoids unnecessary method revalidation and regulatory submissions
■ Reduces downtime and resource consumption during instrument changes
■ Improves confidence in method performance by distinguishing instrument-related effects from method issues
■ Facilitates analytical method transfers within or between laboratories

Future Trends and Potential Applications

■ Extension of iQbD approaches to UHPLC and multi-vendor instrument environments
■ Integration with digital-twin models and AI-driven risk analysis for automated instrument suitability assessment
■ Harmonization with forthcoming USP <1220> and ICH Q14 guidelines for analytical procedure lifecycle management
■ Expansion of standardized QCRMs and test protocols to support a broader range of analytical techniques

Conclusion

The iQbD framework provides a structured, instrument-centric method to assess, control, and validate LC system upgrades or replacements. By focusing on key instrument variables and proactive risk management, laboratories can leverage modern hardware improvements without disrupting validated analytical procedures or incurring extensive revalidation efforts.

Reference

1. ICH Q8(R2) Pharmaceutical Development, Nov 2005, updated Aug 2009.
2. ICH Q9 Quality Risk Management, Nov 2005.
3. ICH Q10 Pharmaceutical Quality System, Jun 2008.
4. Borman PB et al., PharmTech, Oct 2007, Application of QbD to Analytical Methods.
5. Nethercote P et al., Pharmaceutical Manufacturing, Apr 2010, QbD for Method Validation and Transfer.
6. Pharmacopeial Forum, Jan 2017, Proposed USP General Chapter: The Analytical Procedure Lifecycle.
7. MHRA Consultation on Application of AQbD Principles to Pharmacopoeial Standards.
8. USP <1220> The Analytical Procedure Lifecycle (pending).
9. ICH Q14 Analytical Procedure Development (pending).
10. USP <1224> Transfer of Analytical Procedures.
11. FDA 21 CFR Part 211, Sec. 211.68 Automatic, Mechanical, and Electronic Equipment.
12. Burgess C and McDowall RD, Spectroscopy Online, Dec 2020, Life Cycle Approach to Analytical Instruments.
13. Burgess C, Pharmacopeial Forum, 46(4), 2020.
14. Waters QCRM and Benchmarking Instrument Performance, Waters Corp., 2013.
15. Hong P and McConville PR, Waters Corp., Dwell Volume and Extra-Column Volume Impact Method Transfer.
16. Waters Alliance e2695 Instrument Specifications.
17. Waters Arc HPLC Instrument Specifications.